Tag: Immunotherapy
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
Cancer patients with clinically significant immune-related adverse events had significantly lower tolerant fraction
Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
Risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia elevated, but risks lower in recent years
Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy
Fecal Microbiota Transplant Effective for Immune-Mediated Colitis
92 percent of 12 patients with refractory immune checkpoint inhibitor-induced colitis achieved clinical remission at end of study
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer
Overall and progression-free survival increased for persistent, recurrent, or metastatic cervical cancer
Cemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer
Immunotherapy Works Well for Young Children With Peanut Allergy
Significantly more children aged 1 to 3 years receiving epicutaneous immunotherapy had treatment response at 12 months
Patient-Centered Approach Recommended for Oligometastatic NSCLC
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer
